NASDAQ:CMRX - Chimerix Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.00
  • Forecasted Upside: 162.07 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$7.25
▼ -0.12 (-1.63%)

This chart shows the closing price for CMRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Chimerix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CMRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CMRX

Analyst Price Target is $19.00
▲ +162.07% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Chimerix in the last 3 months. The average price target is $19.00, with a high forecast of $21.00 and a low forecast of $14.00. The average price target represents a 162.07% upside from the last price of $7.25.

This chart shows the closing price for CMRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Chimerix. This rating has held steady since March 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/25/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/7/2021HC WainwrightBoost Price TargetBuy$18.00 ➝ $19.00High
5/6/2021HC WainwrightBoost Price TargetBuy$16.00 ➝ $18.00High
4/29/2021Maxim GroupInitiated CoverageBuy$20.00High
4/12/2021JonestradingReiterated RatingBuy$14.00High
3/31/2021Jefferies Financial GroupInitiated CoverageBuy$21.00High
3/31/2021WedbushInitiated CoverageOutperform$21.00High
1/11/2021HC WainwrightBoost Price TargetBuy$7.00 ➝ $16.00High
1/8/2021JonestradingReiterated RatingBuy$10.00High
8/11/2020HC WainwrightReiterated RatingBuy$7.00High
2/26/2020HC WainwrightReiterated RatingBuy$7.00High
8/1/2019HC WainwrightBoost Price TargetBuy$5.00 ➝ $7.00Medium
5/9/2019CowenReiterated RatingHold$3.00High
3/6/2019CitigroupLower Price TargetNeutral ➝ Neutral$4.25 ➝ $2.00Low
2/6/2019HC WainwrightReiterated RatingBuyHigh
10/18/2018CowenReiterated RatingHold$6.00High
9/7/2018HC WainwrightReiterated RatingBuy$10.00High
6/7/2018HC WainwrightReiterated RatingBuy$10.00Low
3/19/2018HC WainwrightReiterated RatingBuy$10.00Low
3/1/2018CowenReiterated RatingHold$6.00Low
2/14/2018JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightLow
2/2/2018HC WainwrightInitiated CoverageBuy ➝ Buy$10.00Low
5/1/2017(FBRC)Reiterated RatingHold$7.00High
4/28/2017CowenReiterated RatingHold$6.00Low
3/4/2017(FBRC)Set Price TargetHold$8.00N/A
2/22/2017(FBRC)Reiterated RatingHoldN/A
1/11/2017(FBRC)Reiterated RatingHold$8.00N/A
10/30/2016(FBRC)Reiterated RatingHoldN/A
8/18/2016Piper Jaffray CompaniesSet Price TargetBuy$12.00N/A
8/9/2016JPMorgan Chase & Co.Reiterated RatingHold$7.00N/A
8/9/2016(FBRC)Lower Price TargetMkt Perform$9.00 ➝ $8.00N/A
(Data available from 7/25/2016 forward)
Chimerix logo
Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 a program for potentially treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $7.25
Low: $7.19
High: $7.42

50 Day Range

MA: $7.95
Low: $7.25
High: $8.76

52 Week Range

Now: $7.25
Low: $2.22
High: $11.57

Volume

331,149 shs

Average Volume

799,158 shs

Market Capitalization

$625.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Chimerix?

The following Wall Street research analysts have issued research reports on Chimerix in the last year: HC Wainwright, Jefferies Financial Group Inc., Jonestrading, Maxim Group, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for CMRX.

What is the current price target for Chimerix?

5 Wall Street analysts have set twelve-month price targets for Chimerix in the last year. Their average twelve-month price target is $19.00, suggesting a possible upside of 162.1%. Jefferies Financial Group Inc. has the highest price target set, predicting CMRX will reach $21.00 in the next twelve months. Jonestrading has the lowest price target set, forecasting a price of $14.00 for Chimerix in the next year.
View the latest price targets for CMRX.

What is the current consensus analyst rating for Chimerix?

Chimerix currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CMRX will outperform the market and that investors should add to their positions of Chimerix.
View the latest ratings for CMRX.

What other companies compete with Chimerix?

How do I contact Chimerix's investor relations team?

Chimerix's physical mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company's listed phone number is 919-806-1074 and its investor relations email address is [email protected] The official website for Chimerix is www.chimerix.com.